| Rite Aid Pharmacy 11251 | |
| 2040 Atlantic Ave, Chesapeake, Virginia 23324 | |
| (757) 543-9632 |
| Name | Rite Aid Pharmacy 11251 |
|---|---|
| Organization Name | Eckerd Corporation |
| Location | 2040 Atlantic Ave, Chesapeake, Virginia 23324 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (757) 543-9632 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The number of cardiovascular procedures performed in Australia is expected to go down in 2020 compared to 2019 due to the COVID-19.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
Today's passage of health care reform in the U.S. Senate is one historic step toward fulfilling what will one day be a promise we will make to every person living in this country: If you are sick, we will care for you.
› Verified 2 days ago
| NPI Number | 1700987583 |
| Organization Name | ECKERD CORPORATION |
| Doing Business As | RITE AID PHARMACY 11251 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2040 Atlantic Avenue, Chesapeake, VA 23324 |
| Phone Number | 757-543-9632 |
News Archive
The number of cardiovascular procedures performed in Australia is expected to go down in 2020 compared to 2019 due to the COVID-19.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
Today's passage of health care reform in the U.S. Senate is one historic step toward fulfilling what will one day be a promise we will make to every person living in this country: If you are sick, we will care for you.
› Verified 2 days ago
News Archive
The number of cardiovascular procedures performed in Australia is expected to go down in 2020 compared to 2019 due to the COVID-19.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
Today's passage of health care reform in the U.S. Senate is one historic step toward fulfilling what will one day be a promise we will make to every person living in this country: If you are sick, we will care for you.
› Verified 2 days ago
1st Choice In-homecare Inc Type: Medicare Supplier Location: 1501 Crossways Blvd, Ste A-c, Chesapeake, Virginia 23320 Phone: (757) 496-2030 | |
Abc Health Care Type: Durable Medical Equipment & Medical Supplies Supplier Location: 818 Professional Pl W, Chesapeake, Virginia 23320 Phone: (757) 826-2600 | |
American Cmg Services Inc Type: Prosthetic/Orthotic Supplier Location: 1521 Technology Dr, Chesapeake, Virginia 23320 Phone: (757) 548-5656 | |
Med Emporium #14 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 701 Battlefield Blvd N, Chesapeake, Virginia 23320 Phone: (757) 312-0133 | |
Chesapeake Eye Physicians Type: Medicare Supplier Location: 560 Kempsville Rd, Chesapeake, Virginia 23320 Phone: (757) 410-9500 |